恒瑞医药(600276.SH)：获得美国FDA孤儿药资格认定

Core Viewpoint - Heng Rui Medicine (600276.SH) has received orphan drug designation from the U.S. FDA for its product, injection of Rui Kang Qu Mo Zhu Dan Tuan combined with Adebali injection and chemotherapy for the treatment of gastric cancer or gastroesophageal junction adenocarcinoma [1] Group 1 - The product is aimed at treating gastric cancer or gastroesophageal junction adenocarcinoma [1] - Orphan drug designation provides opportunities for policy support in product development, registration, and commercialization in the U.S. [1]